Here are five details:
1. Worldwide revenues for the second quarter were $70.7 million, compared to $72.1 million in the same quarter the prior year.
2. Excluding the company’s $3.7 million reduction from the sale of all assets from the cardiothoracic business closure, RTI Surgical’s total revenues increased 3.3 percent year-over-year to $2.2 million.
3. RTI Surgical reported $30 million in gross profits. Excluding the excess inventory charge and purchase accounting impact, the company’s adjusted gross profit was $36.8 million compared to $37 million in the same period in 2017.
4. Net loss regarding common shares was $6.4 million, or $0.10 per diluted common share in the second quarter.
5. At the end of the year, RTI Surgical expects its revenues to range between $280 million and $290 million.
To view the full financial report, click here.
More articles on devices and implants:
NuVasive reports $282M in Q2 revenue — Up 8.5%
Stryker, Zimmer Biomet, Smith & Nephew & more: 9 device company notes
What to expect from NuVasive for 2nd half of 2018 and beyond: 7 key points
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
